Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toby L Simon

Transfusion

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Transfusion|February 1, 2003
Where have all the donors gone? A personal reflection on the crisis in America's volunteer blood programToby L Simon
Transfusion|July 31, 2002
Iron, iron everywhere but not enough to donateToby L Simon
Transfusion|February 28, 2016
Comment on Stotler BA, Schwartz J. How we use WinRho in patients with idiopathic thrombocytopenic purpura. Transfusion 2015:55:2547-50.: This article is a comment on Stotler and Schwartz [2015] DOI: 10.1111/trf.13185Toby L Simon
Transfusion|July 1, 2004
White particulate matter: this time too much precautionToby L Simon
Transfusion|October 15, 2013
Pathogen inactivation and removal methods for plasma-derived clotting factor concentratesRobert Klamroth, Albrecht Gröner, Toby L Simon
Transfusion|August 25, 2023
Why do US source plasma donors stop donating?Michelle Fransen, Mark Becker, Janet Hershman, et al.
Transfusion|January 9, 2007
How we manage requests for recombinant factor VIIa (NovoSeven)Prasad Mathew, Toby L Simon, Kristin E Hunt, et al.
Transfusion|June 4, 2020
Anti-A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital-based cohort studyChristopher Wallenhorst, Ami Patel, Amgad Shebl, et al.
Transfusion|December 16, 2010
Donor return after temporary deferralBrian Custer, Karen S Schlumpf, David Wright, et al.
Transfusion|December 12, 2018
Longitudinal changes in measles antibody titers in plasma donors and minimum antibody levels of immunoglobulin products for treatment of primary immunodeficiencyToby L Simon, Peter FitzGerald, Mirjam Kühne, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Transfusion|February 1, 2003
Where have all the donors gone? A personal reflection on the crisis in America's volunteer blood programToby L Simon
Transfusion|July 31, 2002
Iron, iron everywhere but not enough to donateToby L Simon
Transfusion|February 28, 2016
Comment on Stotler BA, Schwartz J. How we use WinRho in patients with idiopathic thrombocytopenic purpura. Transfusion 2015:55:2547-50.: This article is a comment on Stotler and Schwartz [2015] DOI: 10.1111/trf.13185Toby L Simon
Transfusion|July 1, 2004
White particulate matter: this time too much precautionToby L Simon
Transfusion|October 15, 2013
Pathogen inactivation and removal methods for plasma-derived clotting factor concentratesRobert Klamroth, Albrecht Gröner, Toby L Simon
Transfusion|August 25, 2023
Why do US source plasma donors stop donating?Michelle Fransen, Mark Becker, Janet Hershman, et al.
Transfusion|January 9, 2007
How we manage requests for recombinant factor VIIa (NovoSeven)Prasad Mathew, Toby L Simon, Kristin E Hunt, et al.
Transfusion|June 4, 2020
Anti-A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital-based cohort studyChristopher Wallenhorst, Ami Patel, Amgad Shebl, et al.
Transfusion|December 16, 2010
Donor return after temporary deferralBrian Custer, Karen S Schlumpf, David Wright, et al.
Transfusion|December 12, 2018
Longitudinal changes in measles antibody titers in plasma donors and minimum antibody levels of immunoglobulin products for treatment of primary immunodeficiencyToby L Simon, Peter FitzGerald, Mirjam Kühne, et al.
Pageof 2